The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Managing toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana, MD, Stanford University, Stanford, CA, explores strategies for mitigating immunotherapy-related toxicities in multiple myeloma (MM). She emphasizes effective prophylaxis for cytopenias and infections, advocating the use of intravenous immunoglobulin (IVIg) and steroids, along with growth factors, to manage neutropenia. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Magenta Therapeutics, BMS, Janssen, Sanofi, Oncopeptides, Takeda, Pfizer
Research Funding: Magenta Therapeutics, BMS, Allogene, Janssen, Novartis
